Alessandro Matano

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano et al. · Clinical Cancer Research · 2016 · 321 citations · Full text

Medicine, Oncology, Pharmacology +16

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

Birgit Geoerger, Franck Bourdeaut, Steven G. DuBois et al. · Clinical Cancer Research · 2017 · 191 citations

Medicine, Oncology, Pharmacology +17

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with <i>NRAS</i>-mutant melanoma: Early encouraging clinical activity.

Jeffrey A. Sosman, Muaiad Kittaneh, Martijn P. Lolkema et al. · Journal of Clinical Oncology · 2014 · 128 citations

Life Sciences, Oncology, Pharmacology +17

Using the Oxford Cognitive Screen to Detect Cognitive Impairment in Stroke Patients: A Comparison with the Mini-Mental State Examination

Mauro Mancuso, Nele Demeyere, Laura Abbruzzese et al. · Frontiers in Neurology · 2018 · 68 citations · Full text

Medicine, Neurology, Neuroscience +17

A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.

Jeffrey R. Infante, Geoffrey I. Shapiro, Petronella O. Witteveen et al. · Journal of Clinical Oncology · 2014 · 61 citations

Medicine, Oncology, Pharmacology +16